<DOC>
	<DOCNO>NCT01847430</DOCNO>
	<brief_summary>The purpose study ass long-term persistence immunity hepatitis B adolescent age 15-16 year vaccinate Engerix™-B Kinder infancy . The study also assess immune response challenge dose Engerix™-B Kinder subject .</brief_summary>
	<brief_title>Evaluation Long-term Persistence Immunity Hepatitis B , Adolescents Vaccinated Infancy With Engerix™-B Kinder</brief_title>
	<detailed_description>This MDD update follow Protocol Amendment 1 , date 20 June 2013 . The Protocol amend GSK replace in-house Enzyme-Linked ImmunoSorbent Assay ( ELISA ) use measure anti-HBs ( antibody Hepatitis B surface antigen ) antibody concentration ChemiLuminescence ImmunoAssay ( CLIA ) . Additionally , threshold level prednisone modify reflect dosage normally prescribed adolescent .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Subject 's parent ( ) /guardians , opinion investigator , comply , requirement protocol . A male female , include , 15 16 year age time vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Written inform assent obtain subject addition inform consent sign parent ( ) /LAR ( ) . Healthy subject establish medical history clinical examination enter study . Documented evidence previous vaccination three consecutive dos Engerix™B Kinder Germany : first two dos receive 9 month age third dose receive 18 month age . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination . Child care . Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccine dose . For corticosteroid , mean prednisone ≥ 20 mg/day , equivalent . Inhaled topical steroid allow . Previous hepatitis B vaccination since administration third dose Engerix™B Kinder . History hepatitis B disease . Administration vaccine foreseen study protocol within period start 30 day study vaccine dose , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . History reaction hypersensitivity likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C oral , axillary tympanic route , ≥ 38.0°C rectal route . The preferred route record temperature study axillary . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede study vaccine dose plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Engerix™-B Kinder</keyword>
</DOC>